Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Sep;26(3):292–294. doi: 10.1128/aac.26.3.292

Azlocillin and cefonicid penetration into bone enhanced by probenecid.

J T Summersgill, L G Harrod, M J Raff
PMCID: PMC176154  PMID: 6508259

Abstract

Azlocillin (AZL) and cefonicid (CFD) penetration into rabbit humerus and scapula was evaluated with and without concomitantly administered probenecid. Groups of animals received either 70 mg of AZL intravenously or 20 mg of CFD intramuscularly per kg of body weight; other groups were pretreated with 40 mg of probenecid per kg before the administration of antibiotics. Peak levels of AZL in the sera of animals not receiving probenecid were 76.0 micrograms/ml at 30 min and declined to 7.7 micrograms/ml by 2.0 h. Maximum concentrations in bone were 2.7 micrograms/g in the humerus and 7.1 micrograms/g in the scapula at 1 h. Pretreatment with probenecid significantly elevated levels of AZL in both serum and bone while increasing the half-life in serum from 0.44 to 0.65 h. Maximum drug concentrations in bones of probenecid-pretreated animals were 3.9 and 11.7 micrograms/g in the humerus and scapula, respectively, with detectable levels persisting in bone for up to 4 h. The peak level of CFD alone in serum was 36.7 micrograms/ml at 30 min and declined to 0.86 micrograms/ml at 8 h. Maximum concentrations in bone were 0.66 micrograms/g in the humerus at 1 h and 1.8 micrograms/g in the scapula at 2 h. Pretreatment with probenecid significantly elevated levels of CFD in both serum and bone while increasing the half-life in serum from 1.4 to 2.94 h. Pretreatment with probenecid achieved maximum concentrations of 1.7 and 2.8 micrograms/g in the humerus and scapula, respectively. Detectable levels of CFD persisted in the humerus for up to 4 h and in the scapula for 8 h.

Full text

PDF
292

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Actor P., Uri J. V., Zajac I., Guarini J. R., Phillips L., Pitkin D. H., Berges D. A., Dunn G. L., Hoover J. R., Weisbach J. A. SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels. Antimicrob Agents Chemother. 1978 May;13(5):784–790. doi: 10.1128/aac.13.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gonzalez M. A. A comparison of azlocillin and gentamicin in the treatment of serious infections caused by Pseudomonas aeruginosa. J Antimicrob Chemother. 1983 May;11 (Suppl B):169–174. doi: 10.1093/jac/11.suppl_b.169. [DOI] [PubMed] [Google Scholar]
  4. Malmborg A. S., Alfredsson H., Kusoffsky E., Strandvik B. Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Scand J Infect Dis Suppl. 1981;29:64–69. [PubMed] [Google Scholar]
  5. Neu H. C., Francke E. L., Ortiz-Neu C., Prince A. S. The use of azlocillin to treat serious infections. J Antimicrob Chemother. 1983 May;11 (Suppl B):141–147. doi: 10.1093/jac/11.suppl_b.141. [DOI] [PubMed] [Google Scholar]
  6. Norden C. W., Shaffer M. A. Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Jan;21(1):62–65. doi: 10.1128/aac.21.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Olive S., Mogabgab W. J., Holmes B., Pollock B., Pauling B., Beville R. Treatment of serious Pseudomonas infections with azlocillin. J Antimicrob Chemother. 1983 May;11 (Suppl B):153–158. doi: 10.1093/jac/11.suppl_b.153. [DOI] [PubMed] [Google Scholar]
  8. Pitkin D., Dubb J., Actor P., Alexander F., Ehrlich S., Familiar R., Stote R. Kinetics and renal handling of cefonicid. Clin Pharmacol Ther. 1981 Nov;30(5):587–593. doi: 10.1038/clpt.1981.208. [DOI] [PubMed] [Google Scholar]
  9. Raff M. J., Melo J. C. Anaerobic osteomyelitis. Medicine (Baltimore) 1978 Jan;57(1):83–103. doi: 10.1097/00005792-197801000-00006. [DOI] [PubMed] [Google Scholar]
  10. Schacht P., Arcieri G., Bruck H., Griffith E., Hullman R., Tettenborn D. International clinical experience with azlocillin. J Antimicrob Chemother. 1983 May;11 (Suppl B):215–222. doi: 10.1093/jac/11.suppl_b.215. [DOI] [PubMed] [Google Scholar]
  11. Sterling R. P., Connor D. J., Norman J. C., Cooley D. A. Cefonicid concentrations in serum and atrial tissue during open-heart surgery. Antimicrob Agents Chemother. 1983 May;23(5):790–792. doi: 10.1128/aac.23.5.790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Summersgill J. T., Schupp L. G., Raff M. J. Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam into bone. Antimicrob Agents Chemother. 1982 Apr;21(4):601–603. doi: 10.1128/aac.21.4.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Verbist L. Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms. Antimicrob Agents Chemother. 1979 Aug;16(2):115–119. doi: 10.1128/aac.16.2.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Waldvogel F. A., Papageorgiou P. S. Osteomyelitis: the past decade. N Engl J Med. 1980 Aug 14;303(7):360–370. doi: 10.1056/NEJM198008143030703. [DOI] [PubMed] [Google Scholar]
  15. Wallace R. J., Jr, Niefield S. L., Waters S., Waters B., Awe R. J., Wiss K., Martin R. R., Greenberg S. B. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. Antimicrob Agents Chemother. 1982 Feb;21(2):231–235. doi: 10.1128/aac.21.2.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. White G. W., Malow J. B., Zimelis V. M., Pahlavanzadeh H., Panwalker A. P., Jackson G. G. Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother. 1979 Apr;15(4):540–543. doi: 10.1128/aac.15.4.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. del Rosal P. L. A comparative study of the efficacy and safety of azlocillin and gentamicin in the treatment of serious infections. J Antimicrob Chemother. 1983 May;11 (Suppl B):159–167. doi: 10.1093/jac/11.suppl_b.159. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES